$SEM (Select Medical Holdings Corporation)

$SEM {{ '2016-04-01T04:11:06+0000' | timeago}} • Announcement

Healthcare holdings company $SEM said that it with its subsidiaries, Select Medical Corporation and Select Medical of New York, Inc., have signed a Stock Purchase Agreement and sold its contract therapy business to an affiliate of Encore Rehabilitation Services for $65MM in cash.

$MD {{ '2018-01-10T15:20:12+0000' | timeago}} • Announcement

$MD announced the acquisition of Tri-Valley Neonatal Medical Group, Inc., a private neonatology physician practice based in California. This was a cash transaction and it is expected to be immediately accretive to earnings. No additional terms of the transaction were disclosed.

$SEM {{ '2018-01-09T18:17:01+0000' | timeago}} • Announcement

$SEM announced a JV agreement with Banner Health to combine operations of more than 38 physical therapy centers in Arizona and four acute inpatient rehabilitation hospitals in Phoenix. Banner Health will be the majority owner and $SEM will serve as managing partner.

$SEM {{ '2018-01-08T18:16:59+0000' | timeago}} • Announcement

$SEM expects consolidated net operating revenues for full year 2018 to be $5-5.2Bil. Adjusted EBITDA is expected to be $630-660MM. $SEM expects fully diluted income per common share for full year 2018 to be $0.97-1.12.

$PRGO {{ '2018-01-08T12:05:55+0000' | timeago}} • Announcement

$PRGO named Uwe Rohrhoff as CEO, effective Jan. 15, 2018, following the retirement of John Hendrickson. Rohrhoff was the former CEO at Gerresheimer AG. Hendrickson to remain with the company until March 15, 2018 to ensure successful transition.

$OMI {{ '2018-01-05T13:04:48+0000' | timeago}} • Announcement

Healthcare solutions firm $OMI plans to organize into two units, named Global Solutions and Global Products. The move is in connection with the acquisition and integration of Halyard Health’s Surgical & Infection Prevention business. Global Solutions will contain most of Owens’ legacy business, while Global Products will contain its S&IP business.

$PFE {{ '2018-01-04T13:11:11+0000' | timeago}} • Announcement

Arvinas LLC collaborates with $PFE for the discovery and development of drug candidates using Arvinas' PROTAC Platform, a novel technology used to create small molecule therapeutics aimed at degrading disease-causing cellular proteins. Arvinas may receive up to $830MM in upfront and potential development and commercialization milestone payments.

$PFE {{ '2017-12-26T12:25:28+0000' | timeago}} • Announcement

$PFE and $MRK announced that the US FDA has approved STEGLATRO (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets for adults with type 2 diabetes.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$MRK {{ '2017-12-22T16:34:34+0000' | timeago}} • Announcement

$MRK and $PFE announced that the FDA approved STEGLATROTM (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets.

$PFE {{ '2017-12-21T21:14:41+0000' | timeago}} • Announcement

$PFE announced that the US FDA has granted Breakthrough Therapy Designation for avelumab in combination with INLYTA for treatment-naive patients with advanced renal cell carcinoma (RCC). This is the second Breakthrough Therapy Designation granted to avelumab.

$PFE {{ '2017-12-20T12:23:04+0000' | timeago}} • Announcement

The US FDA has approved $PFE's supplemental New Drug Application to expand the indication for BOSULIF  to include adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph CML).

$HUM {{ '2017-12-19T15:27:46+0000' | timeago}} • Announcement

$HUM signed a definitive agreement to acquire a 40% minority interest in the Kindred at Home Division of $KND for an estimated cash consideration of approximately $800MM. Humana does not anticipate a material impact to earnings in 2017 from this pending transaction.

$KND {{ '2017-12-19T13:44:51+0000' | timeago}} • Announcement

$KND's BoD approved a definitive agreement whereby it will be acquired by a consortium of three companies: TPG Capital, Welsh, Carson, Anderson & Stowe and $HUM for about $4.1Bil in cash including the assumption or repayment of net debt. The transaction is expected to close during the summer of 2018.

$PFE {{ '2017-12-18T19:31:58+0000' | timeago}} • Announcement

The BoD of $PFE has increased the quarterly dividend by 6% to $0.34 per share. The first quarter 2018 cash dividend will be payable on March 1, 2018, to shareholders of record on Feb. 2, 2018. The board also authorized a new $10Bil share repurchase program, in addition to the $6.4Bil remaining under the current authorization.

$CYH {{ '2017-12-14T13:11:35+0000' | timeago}} • Announcement

$CYH elected Michael Dinkins and Ranga Krishnan to the Board of Directors for terms that will expire at the 2018 Annual Meeting of Stockholders. As part of a settlement in a derivative action lawsuit finalized in January 2017, the company sought the names of prospective candidates for the BoD from its stockholders.

$DGX {{ '2017-12-12T17:19:29+0000' | timeago}} • Announcement

$DGX completed the previously announced acquisition of the Shiel Medical Laboratory business from Fresenius Medical Care, the company focused on delivering care to people with renal and other chronic conditions.

$LLY {{ '2017-12-11T17:36:13+0000' | timeago}} • Announcement

FDA accepts to review $LLY's Galcanezumab, an injectionable drug for the treatment of migraine. Rivals $NVS and $AMGN already filed their migraine drug with FDA in July 2017, while $TEVA is also expected to join the race. Lilly's pain portfolio also includes Tanezumab, developed in partnership with $PFE, for the treatment of osteoarthritis.

$JCI {{ '2017-12-11T16:43:09+0000' | timeago}} • Announcement

$JCI's BoD appointed John Young to serve as a director. Young is currently group president of $PFE Essential Health. Effective Jan. 1, 2018, he will become group president of Pfizer Innovative Health, which comprises six business groups focused on improving health through innovative products covering every stage of life.

$ENSG {{ '2017-12-07T17:03:54+0000' | timeago}} • Announcement

$ENSG's BoD declared a quarterly cash dividend of $0.045 per share of its common stock. The dividend is payable on or before Jan. 31, 2018, to shareholders of record as of Dec. 31, 2017.

$DGX {{ '2017-12-01T19:47:03+0000' | timeago}} • Announcement

$DGX said it completed the acquisition of Cleveland HeartLab. Pursuant to the deal, Quest has entered into collaboration with Cleveland Clinic to speed up commercialization of emerging innovations at Cleveland, including its Lerner Research Institute. The companies also plan to collaborate on clinical trials.

Recent Transcripts

PBYI (Puma Biotechnology, Inc.)
Thursday, November 9 2017 - 9:30pm
ENSG (The Ensign Group, Inc.)
Thursday, November 9 2017 - 6:00pm
QHC (Quorum Health Corporation)
Thursday, November 9 2017 - 4:00pm
FVE (Five Star Quality Care Inc.)
Thursday, November 9 2017 - 3:00pm
CNCE (Concert Pharmaceuticals, Inc.)
Thursday, November 9 2017 - 1:30pm
PRGO (Perrigo Company Public Limited Company)
Thursday, November 9 2017 - 1:00pm
OPK (Opko Health, Inc.)
Wednesday, November 8 2017 - 9:30pm
DVA (DaVita HealthCare Partners Inc.)
Tuesday, November 7 2017 - 10:00pm
BKD (Brookdale Senior Living Inc.)
Tuesday, November 7 2017 - 2:00pm
KND (Kindred Healthcare Inc.)
Tuesday, November 7 2017 - 2:00pm
SEM (Select Medical Holdings Corporation)
Friday, November 3 2017 - 1:00pm
FMS (Fresenius Medical Care AG & Co. KGAA)
Thursday, November 2 2017 - 8:30pm
CYH (Community Health Systems, Inc.)
Thursday, November 2 2017 - 3:00pm
USPH (US Physical Therapy Inc.)
Thursday, November 2 2017 - 2:30pm
NVO (Novo Nordisk A/S)
Thursday, November 2 2017 - 1:16pm
PBH (Prestige Brands Holdings, Inc.)
Thursday, November 2 2017 - 12:30pm
CSU (Capital Senior Living Corp.)
Wednesday, November 1 2017 - 9:00pm
MD (MEDNAX, Inc.)
Wednesday, November 1 2017 - 2:00pm
EVHC (Envision Healthcare Holdings, Inc.)
Wednesday, November 1 2017 - 12:30pm
OMI (Owens & Minor Inc.)
Wednesday, November 1 2017 - 12:00pm

AlphaGraphics you may like